What Is the Clinical Evidence for Cell-Based Therapy in Rheumatoid Arthritis?
Published November 16, 2026
Protocol: 8 steps in this guide
Cell-based therapy for rheumatoid arthritis (RA) is still experimental, and whether it works is uncertain. Researchers are testing it, mainly with mesenchymal stromal cells, because these cells may calm the immune system. A 2025 analysis of registered trials found that RA was the subject of 63 stem cell trials, about 12.6% of trials in autoimmune rheumatic diseases. Counting trials, however, is not the same as showing benefit: one published placebo-controlled trial of 53 patients found the cells generally well tolerated and reported only “a trend for clinical efficacy,” and no cell product is approved for RA. Standard care with disease-modifying drugs, directed by a rheumatologist, remains the treatment.
Autoimmune synovitis is not osteoarthritis
RA and osteoarthritis are different diseases, so evidence from one cannot be borrowed for the other. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) explains on its rheumatoid arthritis page that RA “occurs when the immune system, which normally helps protect the body from infection and disease, attacks its own tissues.” Immune cells inflame the lining of the joint, the synovium, which thickens and, as the disease progresses, “destroys the cartilage and bone within the joint.” Cell injections studied for knee osteoarthritis, covered in what clinical trials show about stem cell injections for knee osteoarthritis, are aimed at a different problem.
The immune-modulation theory
Mesenchymal stromal cells (MSCs) are studied in autoimmune disease for their effects on immune cells rather than for building tissue. The 2025 trial analysis, by Xu and colleagues in the International Journal of Surgery, Clinical trial landscape analysis of stem cell therapy for autoimmune rheumatic diseases, describes MSCs as favored for their “immunomodulatory functions.” An immune effect seen in the laboratory is a reason to test a treatment, not evidence that it helps people with RA. What MSCs are is explained in what mesenchymal stromal cells are.
What the trial landscape shows
The Xu analysis is a map of research activity, not a test of whether treatments work. It drew on the Informa Trialtrove database and ClinicalTrials.gov, as of March 31, 2025. Its findings across autoimmune rheumatic diseases:
| Measure | Finding |
|---|---|
| Cell type | MSCs in 75.8% of trials |
| Conditions | Osteoarthritis 46.7%, lupus 16.0%, RA 12.6% (63 trials) |
| Countries | China 26.7%, United States 14.4%, South Korea 9.8% |
| Status | 58.8% completed; 13.1% terminated |
The authors note that terminations resulted from “poor recruitment, lack of therapeutic efficacy, regulatory hurdles, or financial limitations,” and conclude that “large-scale, multicenter, phase III trials with standardized designs” are needed “to clearly determine the efficacy and safety of stem cell therapy.” The text also gives a total of 449 trials, while its percentages match a total of 499; that inconsistency does not change the RA count of 63.
A published controlled trial: Cx611
Registry counts are not results. One published randomized, placebo-controlled trial shows what early human evidence looks like. In a 2017 phase Ib/IIa trial in the Annals of the Rheumatic Diseases, Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611), people with active RA that had not responded to at least two biologic drugs received three intravenous infusions of donor fat-derived stem cells grown in a laboratory, at one of three doses, or placebo.
| Feature | What the trial reported |
|---|---|
| Design | Multicentre, dose escalation, randomised, single-blind (double-blind for efficacy), placebo-controlled |
| Patients treated | 53: 20, 20 and 6 at the three doses; 7 placebo |
| Treatment and follow-up | Infusions on days 1, 8 and 15; followed for 24 weeks |
| Adverse events | At least one in 85%, 75% and 100% of the three dose groups and 57% of placebo; 8 severe events, of which one, a lacunar infarction, was serious |
| ACR20 response at month 1 | 45%, 20% and 33% at the three doses; 29% with placebo |
| ACR20 response at month 3 | 25%, 15% and 17% at the three doses; 0% with placebo |
The authors described the infusions as “in general well tolerated” and reported “a trend for clinical efficacy,” which in their view justified further investigation. The placebo group’s response changed from 29% at month 1 to 0% at month 3, which shows how much small groups can swing. With groups of 6 to 20 people and 24 weeks of follow-up, this is a safety and dose-finding study, not proof that the cells work.
Early safety trials versus efficacy trials
A registered trial can be an early study testing whether a treatment is tolerable, or a later trial testing whether it works better than a comparison. The Xu analysis calls for phase III trials precisely because those later, larger trials are what establish efficacy. A completed early-phase study, or a listing on ClinicalTrials.gov, does not show that a treatment helps, as explained in whether listing a study on ClinicalTrials.gov means a treatment is approved. Before relying on any RA cell trial, look for its published results against a control group; a registration alone does not provide them.
Standard care with a rheumatologist
The established treatment for RA is medicine that changes the course of the disease. NIAMS, on its page on diagnosis, treatment and steps to take, lists disease-modifying antirheumatic drugs (DMARDs) “that can help to slow or change the progression of the disease,” including biologic response modifiers and JAK inhibitors. It stresses timing: once joint damage occurs, it “generally cannot be reversed, so early diagnosis and treatment are very important.” Anyone considering a cell treatment should not stop prescribed RA medicines without their rheumatologist’s advice; NIAMS notes that flares can follow “suddenly stopping medications.”
Safety in people on immune-suppressing treatment
NIAMS notes: “Many of the medications used to treat rheumatoid arthritis may increase the risk of infection.” Adding an experimental cell product to that situation raises questions about infection and immune reactions that a trial should monitor closely. The Xu analysis lists a “lack of long-term safety data” among the remaining challenges. Immune risks of donor cells are covered in the risks of immune reactions to donor-derived cell products.
Regulatory status
FDA’s patient and consumer information on regenerative medicine therapies states that the unapproved regenerative products it warns about “have not been approved for the treatment of any orthopedic condition.” The one FDA-approved MSC product, Ryoncil, is approved for steroid-refractory acute graft-versus-host disease in children, not for RA. A cell treatment for RA in the United States belongs in a clinical trial with ethics oversight and, where the product requires one, an FDA investigational new drug application in effect; a ClinicalTrials.gov listing alone does not replace it, as explained in what it means when an FDA investigational new drug application is in effect.
Cell-based therapy for rheumatoid arthritis is an active research area, with 63 registered trials in one 2025 analysis, but its effectiveness has not been established by large controlled trials, so it is not a substitute for rheumatologist-directed DMARD treatment.
Cells linked to this one
This guide leads on to
- F1 What Do Clinical Trials Show About Stem Cell Injections for Knee Osteoarthritis?
- E2 What Are Mesenchymal Stromal Cells (MSCs)?
- I3 Does Listing a Study on ClinicalTrials.gov Mean a Treatment Is Approved?
- E10 What Are the Risks of Immune Reactions to Donor-Derived Cell Products?
- I2 What Does It Mean When an FDA Investigational New Drug (IND) Application Is in Effect?
Add a remark